In the case of GBM, most of the genetic alterations in CDKN2A, PTEN and TP53 were deletions or mutations (Figure 3B), which resulted in a reduction of their expression in conjunction with the development of carcinogenesis [34, 35]. Here, CDKN2A is linked to glioblastoma.